AİLE PLANLAMASI YÖNTEMLERİNDE GÜNCEL GELİŞMELER

Yıl 2018, Cilt: 4 Sayı: 1, - , 08.06.2018

Neslihan Değerli Kodaz Kamile Altuntuğ Emel Ege

Öz

Kontrasepsiyon ihtiyacı erken cinsel
deneyim ve geç menopoz nedeniyle 30 yıl kadar devam etmektedir. Kontrasepsiyon
kadınların mesleki kariyer ve çalışma planını hesaba katarak, gebeliklerini
sayı ve zaman açısından planlama fırsatı verir. Güvenilir kontrasepsiyonla
istenmeyen gebelik korkusu, yasa dışı düşük ve doğum kaynaklı ölümleri önlemek
mümkündür. 

Kadınların
birtakım farklı ihtiyaçlarının karşılanması, erken dönemde yöntem bırakmanın
önlenmesi ve yöntem yan etkilerinin azaltılması amacıyla yeni kontraseptif
yöntemler geliştirilmiştir. Kadına ait yöntemlerde yenilikler kombine
kontraseptif formulasyonlar, kombine transdermal formulasyonlar, kombine
kontraseptif vajinal halkalar, sadece progesteron içeren sistemler (implantlar,
vajinal halkalar), bariyer yöntemler, intrauterin sistemler, histeroskopik
sterilizasyon teknikleri ve acil kontrasepsiyondaki gelişmelerdir. Erkeğe ait
yöntemlerde yenilikler ise hormonal yöntemler ve hormonal olmayan yöntemlerdeki
gelişmelerdir.

Sağlık personeli kontraseptif danışmanlıkta hasta ve
kontraseptif yöntem arasındaki en iyi uyumu oluşturmak için güncel bilgiye
ulaşmalıdır. Aynı zamanda, sağlık personelinin kadınlara bazı özel tıbbi
durumlarda da kontraseptif sağlaması gerekebilir. Çiftlerin kendilerine uygun
aile planlaması yöntemini bilerek tercih etmelerine yardım etmek için
yöntemlerle ilgili bilgi verilmelidir. Aile planlaması kliniklerinin kullanımı
sunulan kontraseptif seçeneklerin çeşitliliği ile doğrudan ilgilidir. 

Anahtar Kelimeler

Aile Planlaması, Kontrasepsiyon, Gebelik, Güncel Gelişmeler

Kaynakça

• Attardi, B. J., Engbring, J. A., Gropp, D. ve Hild, S. A., 2011, Development of Dimethandrolone 17β‐Undecanoate (DMAU) as an Oral Male Hormonal Contraceptive: Induction of Infertility and Recovery of Fertility in Adult Male Rabbits, Journal of andrology, 32 (5), 530-540.
• Bahamondes, L. ve Bahamondes, M. V., 2014, New and emerging contraceptives: a state-of-the-art review, International Journal of Women’s Health, 6, 221-234.
• Black, A., Guilbert, E., Co, A., Costescu, D., Dunn, S., Fisher, W., Kives, S., Mirosh, M., Norman, W. V., Pymar, H., Reid, R., Roy, G., Varto, H., Waddington, A., Wagner, M. S., Whelan, A. M., Special, C., Ferguson, C., Fortin, C., Kielly, M., Mansouri, S. ve Todd, N., 2015, Canadian Contraception Consensus (Part 2 of 4), J Obstet Gynaecol Can, 37 (11), 1033-1039.
• Bonnema, R. A. ve Spencer, A. L., 2011, The new extended-cycle levonorgestrel-ethinyl estradiol oral contraceptives, Clin Med Insights Reprod Health, 5, 49-54.
• Brache, V., Croxatto, H., Kumar, N., Sitruk-Ware, R., Cochón, L., Schiappacasse, V., Sivin, I., Muñoz, C., Maguire, R. ve Faundes, A., 2009, Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study, Contraception, 79 (2), 150-154.
• Brache, V., Merkatz, R., Kumar, N., Jesam, C., Sussman, H., Hoskin, E., Roberts, K., Alami, M., Taylor, D., Jorge, A., Croxatto, H., Lorange, E., Mishell, D. R. ve Sitruk-Ware, R., 2015, A dose-finding, cross-over study to evaluate the effect of a Nestorone(R)/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women, Contraception, 92 (4), 289-297.
• Calliope, 2017, The Contraceptive Pipeline Database, https://pipeline.ctiexchange.org/products?&&&&&&&&&field sponsors tid[0]=471
• Chaki, S. P., Das, H. C. ve Misro, M. M., 2003, A short-term evaluation of semen and accessory sex gland function in phase III trial subjects receiving intravasal contraceptive RISUG, Contraception, 67 (1), 73–78.
• Cheng, L., Che, Y. ve Gülmezoglu, A. M., 2012, Interventions for emergency contraception, Cochrane Database of Systematic Reviews (8), CD001324.
• Clark, J. T., Clark, M. R., Shelke, N. B., Johnson, T. J., Smith, E. M., Andreasen, A. K., Nebeker, J. S., Fabian, J., Friend, D. R. ve Kiser, P. F., 2014, Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy, PLoS One, 9 (3), e88509.
• Contraceptive Independence, 2016, Jadelle®Contraceptive Independence, http://www.jadelle.com/static/documents/Jadelle General Brochure.pdf
• Cox, M., Tripp, J. ve Blacksell, S., 2002, Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report, Journal of Family Planning and Reproductive Health Care, 28 (2), 73-77.
• Dhont, M., 2010, History of oral contraception, Eur J Contracept Reprod Health Care, 15 Suppl 2, S12-18.
• Doğum Kontrol Flasteri (Evra), 2016, Doğum Kontrol Flasteri (Evra) http://www.e-gebelik.net/aile%20planlamasi/yeni yontemler/dogum kontrol flasteri evra.asp
• Doğum Kontrol Metodları, 2016, Doğum Kontrol Metodları, http://www.dr-hsenyurt.com/dogum-kontrol.html
• Evlilik Öncesi Danışmanlık Rehberi, 2014, Evlilik Öncesi Danışmanlık Rehberi, http://sbu.saglik.gov.tr/Ekutuphane/kitaplar/Evlilikoncesi%20DanismanlikRehberi.pdf
• FDA Approved Drug Products, 2001, Drugs@FDA FDA Approved Drug Products, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
• Fraser, I. S., Weisberg, E., Kumar, N., Kumar, S., Humberstone, A. J., McCrossin, L., Shaw, D., Tsong, Y. Y. ve Sitruk-Ware, R., 2007, An initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptive, Contraception, 76 (6), 432-438.
• Goldstuck, N. D., 2014, Reducing Barriers to the use of the Intrauterine Contraceptive Device as a Long Acting Reversible Contraceptive, African Journal of Reproductive Health, 18 (4), 15-25.
• Gu, Y., Liang, X., Wu, W., Liu, M., Song, S., Cheng, L., Bo, L., Xiong, C., Wang, X., Liu, X., Peng, L. ve Yao, K., 2009, Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men, J Clin Endocrinol Metab, 94 (6), 1910-1915.
• Hamburg, M. A., 2011, Premarket Approval of Pediatric Uses of Devices – FY 2009-2011, U.S. Department of Health and Human Services.
• Highlights of Prescribing Information, 2015, Highlights of Prescribing Information, http://labeling.bayerhealthcare.com/html/products/pi/natazia pi.pdf
• Hofmeyr, G. J., Singata, M. ve Lawrie, T. A., 2010, Copper containing intra-uterine devices versus depot progestogens for contraception., Cochrane Database of Systematic Reviews, 16 (6), CD007043.
• Huang, Y., Jensen, J. T., Brache, V., Cochon, L., Williams, A., Miranda, M. J., Croxatto, H., Kumar, N., Sussman, H., Hoskin, E., Plagianos, M., Roberts, K., Merkatz, R., Blithe, D. ve Sitruk-Ware, R., 2014, A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception, Contraception.
• Hugon-Rodin, J., Chabbert-Buffet, N. ve Bouchard, P., 2010, The future of women’s contraception: stakes and modalities, Annals of the New York Academy of Sciences, 1205, 230-239.
• Ilani, N., Roth, M. Y., Amory, J. K., Swerdloff, R. S., Dart, C., Page, S. T., Bremner, W. J., Sitruk-Ware, R., Kumar, N., Blithe, D. L. ve Wang, C., 2012, A New Combination of Testosterone and Nestorone Transdermal Gels for Male Hormonal Contraception, Journal of Clinical Endocrinology & Metabolism, 97 (10), 3476-3486.
• Implanon, 2016, Implanon™ http://www.accessdata.fda.gov/drugsatfda docs/label/2009/021529s004lbl.pdf
• Jacobson, J. C., Likis, F. E. ve Murphy, P. A., 2012, Extended and continuous combined contraceptive regimens for menstrual suppression, J Midwifery Womens Health, 57 (6), 585-592.
• Jadav, S. P. ve Parmar, D. M., 2012, Ulipristal acetate, a progesterone receptor modulator for emergency contraception, J Pharmacol Pharmacother, 3 (2), 109-111.
• Jensen, J. T., 2011, The future of contraception: innovations in contraceptive agents: tomorrow's hormonal contraceptive agents and their clinical implications, Am J Obstet Gynecol, 205 (4 Suppl), S21-25.
• Koyama, A., Hagopian, L. ve Linden, J., 2013, Emerging options for emergency contraception, Clin Med Insights Reprod Health, 7, 23-35.
• Lawrie, T. A., Nardin, J. M., Kulier, R. ve Boulvain, M., 2011, Techniques for the interruption of tubal patency for female sterilisation, Cochrane Database Syst Rev., 16 (2), CD003034.
• Lendvay, A., Otieno-Masaba, R., Azmat, S. K., Wheeless, A., Hameed, W., Shaikh, B. T., Kuria, S., Steiner, M. J., Chen, M. ve Feldblum, P. J., 2014, Effectiveness, safety and acceptability of Sino-implant (II) during the first year of use: results from Kenya and Pakistan, Contraception, 89 (3), 197-203.
• Leoci, R., Aiudi, G., Silvestre, F., Lissner, E. A., Marino, F. ve Lacalandra, G. M., 2015, Therapeutic Ultrasound as a Potential Male Dog Contraceptive: Determination of the Most Effective Application Protocol, Reproduction in Domestic Animals, 50 (5), 712-718.
• Levonorgestrel Releasing Intrauterine System, 2013, Levonorgestrel, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
• Levonorgestrel Releasing Intrauterine System, 2016, Levonorgestrel Releasing Intrauterine System, http://www.accessdata.fda.gov/drugsatfda docs/label/2008/021225s019lbl.pdf
• LNG ICD, 2017, Levonorgestrel (LNG) Intracervical Device (ICD), https://pipeline.ctiexchange.org/products/lng-icd
• Lopez, L. M., Grimes, D. A., Gallo M, F., Stockton, L. L. ve Schulz, K. F., 2013, Skin patch and vaginal ring versus combined oral contraceptives for contraception, Cochrane Database of Systematic Reviews, 30 (4), CD003552.
• Lu, W. H., Liang, X. W., Gu, Y. Q., Wu, W. X., Bo, L. W., Zheng, T. G. ve Chen, Z. W., 2014, A randomized, controlled, multicenter contraceptive efficacy clinical trial of the intravas device, a nonocclusive surgical male sterilization, Asian J Androl, 16 (3), 432-436.
• Magon, N., Chauhan, M., Goel, P., Malik, S., Kapur, K., Kriplani, A., Dhaliwal, L. ve Pandit, S. N., 2013, Levonorgestrel intrauterine system: Current role in management of heavy menstrual bleeding, J Midlife Health, 4 (1), 8-15.
• malecontraceptives, 2016, malecontraceptives.org, https://www.malecontraceptive.org/
• Meirik, O., Rowe, P. J., Peregoudov, A., Piaggio, G., Petzold, M., Iud Research Group at the Undp/Unfpa/Who/World Bank Special Programme of Research, D. ve Research Training in Human, R., 2009, The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial, Contraception, 80 (2), 133-141.
• Mifeprex, 2000, Mifeprex, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
• Mifeprex (mifepristone) Information, 2016, Mifeprex (mifepristone) Information, http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111323.htm
• Mohamed, A. M., El-Sherbiny, W. S. ve Mostafa, W. A., 2011, Combined contraceptive ring versus combined oral contraceptive (30-µg ethinylestradiol and 3-mg drospirenone), International Journal of Gynecology and Obstetrics, 114 (2), 145-148.
• Mulders, T. M., Dieben, T. O. ve Bennink, H. J., 2002, Ovarian function with a novel combined contraceptive vaginal ring., Hum Reprod, 17 (10), 2594-2599
• NES Implant, 2016, NES Implant, http://pipeline.ctiexchange.org/products/nes-implant
• Nestorone/Estradiol Transdermal Gel Contraception, 2016, Nestorone®/Estradiol Transdermal Gel Contraception, http://www.popcouncil.org/research/nestorone-estradiol-transdermal-gel-contraception
• Nexplanon, 2016, Nexplanon, http://www.accessdata.fda.gov/drugsatfda docs/label/2015/021529s011lbl.pdf
• Nuvaring Vajinal Halka, 2005, Nuvaring Vajinal Halka, http://www.msd.com.tr/Style%20Library/CountrySite/Turkey/Turkish/pdfs/NUVARING Vajinal Halka KUB.pdf
• Obare, F., Rajamani, D. ve S., R., 2014, Assessing the potential market for a progesterone contraceptive vaginal ring (pcvr) as a new contraceptıve option in sub-saharan africa using needs-based market segmentatıon.
• One size contraceptive diaphragm, 2016, New Product Review from the Clinical Effectiveness Unit One size contraceptive diaphragm (Caya®), https://www.google.com.tr/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwiZsKrBxJnTAhVD6xoKHZ7dCHYQFggeMAA&url=https%3A%2F%2Fwww.fsrh.org%2Fdocuments%2Fcec-ceu-newproductreview-caya-aug-2014%2Fcec-ceu-newproductreview-caya-aug-2014.pdf&usg=AFQjCNE4wwvnzohLQds1AO7MlcnTwJ57HA&bvm=bv.152180690,d.d2s
• Oral Contraceptive Reference Chart, 2014, Oral Contraceptive Reference Chart, http://www.rmhp.org/docs/default-source/provider/oral contraceptive reference chart.pdf?sfvrsn=7
• Piaggio, G., Kapp, N. ve von Hertzen, H., 2011, Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials, Contraception, 84 (1), 35-39.
• Population Council, 2016, Population Council, http://www.popcouncil.org/
• Rahim İçi Araçlar, 2016, Rahim İçi Araçlar, http://sbu.saglik.gov.tr/Ekutuphane/kitaplar/a%C3%A7sap35.pdf
• Roth, M. Y., Shih, G., Ilani, N., Wang, C., Page, S. T., Bremner, W. J., Swerdloff, R. S., Sitruk-Ware, R., Blithe, D. L. ve Amory, J. K., 2014, Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial, Contraception, 90 (4), 407-412.
• Sanhal, C. Y., Ulukuş, M. ve İtil, İ. M., 2012, Kontrasepsiyonda Güncel Gelişmeler, Türk Jinekoloji ve Obstetrik Derneği Dergisi, 9 (2 ), 85- 93.
• Schuurman, T. ve Veersema, S., 2011, Successful placement of the Essure device after a failed procedure using the Adiana system for hysteroscopic sterilisation, BMJ Case Rep, 2011.
• Sitruk-Ware, R., Small, M., Kumar, N., Tsong, Y. Y., Sundaram, K. ve Jackanicz, T., 2003, Nestorone®: clinical applications for contraception and HRT, Steroids, 68 (10-13), 907-913.
• Sitruk-Ware, R., Brache, V., Maguire, R., Croxatto, H., Kumar, N., Kumar, S., Montero, J. C., Salvatierra, A. M., Phillips, D. ve Faundes, A., 2007, Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraception, Contraception, 75 (6), 454-460.
• Sitruk-Ware, R., Nath, A. ve Mishell, D. R., Jr., 2013, Contraception technology: past, present and future, Contraception, 87 (3), 319-330.
• Skyla, 2016, Skyla, http://www.skyla-us.com/index.php
• Summary of Safety and Effectıveness Data, 2002, Summary of Safety and Effectıveness Data, http://www.accessdata.fda.gov/cdrh docs/pdf2/p020014b.pdf
• Taylor, T. N., Farkouh, R. A., Graham, J. B., Colligs, A., Lindemann, M., Lynen, R. ve Candrilli, S. D., 2011, Potential reduction in neural tube defects associated with use of Metafolin-fortified oral contraceptives in the United States, Am J Obstet Gynecol, 205 (5), 460 e461-468.
• Thakur, V., Choudhary, M., Mehta, V. ve Kumar, D., 2013, RISUG: A new perspective in non–hormonal male contraception, Asian Pacific Journal of Reproduction, 2 (2), 159–162.
• The Essure Permanent Birth Control System, 2016, A New Method of Permanent Birth Control: The essure Permanent Birth Control System, http://www.fda.gov/ohrms/dockets/ac/02/briefing/3881b1 04.pdf
• Today sponge contraceptive sponge, 2007, Today sponge contraceptive sponge http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi id=874974
• Trussell, J., Raymond, E. G. ve Cleland, K., 2014, Emergency contraception: a last chance to prevent unintended pregnancy, Contemp. Readings L. & Soc. Just., 6, 7.
• Türk, R. ve Terzioğlu, F., 2012, Geri Çekme Yöntemi ve Kullanımını Etkileyen Faktörler, Ankara Sağlık Bilimleri Dergisi, 1 (3), 67-80.
• Türkiye Nüfus ve Sağlık Araştırması, 2013, Türkiye Nüfus ve Sağlık Araştırması, Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü.
• Ulipristal Acetate, 2010, Ulipristal Acetate, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
• US Food and Drug Administration, 2001, U.S. Food and Drug Administration, http://www.fda.gov/default.htm
• VandeVoort, C. A. ve Tollner, T. L., 2012, The efficacy of ultrasound treatment as a reversible male contraceptive in the rhesus monkey, Reproductive Biology and Endocrinology, 10.
• Vasalgel Faq’s, 2016, Vasalgel Faq’s, http://www.parsemusfoundation.org/projects/vasalgel/vasalgel-faqs
• What is essure, 2016, What is essure, www.essure.com/what-is-essure
• Wildemeersch, D., 2007, New frameless and framed intrauterine devices and systems - an overview, Contraception, 75 (6 Suppl), S82-S92.
• Wildemeersch, D., Janssens, D. ve Andrade, A., 2009, The Femilis LNG-IUS: contraceptive performance-an interim analysis, European Journal of Contraception and Reproductive Health Care, 14 (2), 103-110.
• Wildemeersch, D. ve Andrade, A., 2010, Review of clinical experience with the frameless LNG-IUS for contraception and treatment of heavy menstrual bleeding, Gynecol Endocrinol, 26 (5), 383-389.
• Wildemeersch, D., 2012, The LNG-IUS: The First Choice Alternative to Hysterectomy? Intrauterine Levonorgestrel-Releasing Systems for Effective Treatment and Contraception, INTECH Open Access Publisher.